Neurology
-
Randomized Controlled Trial Multicenter Study Clinical Trial
A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients.
Citicoline may reduce CNS ischemic injury by stabilizing cell membranes and reducing free radical generation. Previous safety and efficacy trials in patients who have had acute strokes suggested that citicoline may improve neurologic outcome with minimal side effects. ⋯ Citicoline was safe but ineffective in improving the outcome of patients with acute ischemic stroke as measured by the planned analyses. Post hoc analyses suggest that a modest treatment effect may have been seen if more traditional analyses had been used.